Ophthalmic Surg Lasers Imaging Retina. 2023 Feb;54(2):84-88. doi: 10.3928/23258160-20230130-01. Epub 2023 Feb 1.
We report our initial experience with intravitreal bevacizumab-bvzr, a bevacizumab biosimilar approved by the US Food and Drug Administration in 2019 and recently introduced by our institution for off-label ophthalmologic use in children.
This was an Institutional Review Board-approved single-institution retrospective case series of pediatric patients 21 years or younger who received at least one intravitreal injection of biosimilar bevacizumab-bvzr.
Twelve eyes of 9 patients were identified as having received intravitreal bevacizumab-bvzr, with a total of 13 injections performed. Indications for injection included retinopathy of prematurity (7/13), choroidal neovascularization (3/13), retinal vein occlusion (2/13), and Coats disease (1/13). Following injection of bevacizumab-bvzr, all patients experienced a positive clinical response. No occurrences of postinjection inflammation, intraocular pressure anomalies, or endophthalmitis were observed with a median follow-up of 18 weeks.
In the absence of controlled studies, this case series supports the use of intravitreal bevacizumab-bvzr as an anti-vascular endothelial growth factor therapy option, including in the pediatric population and resource-poor settings. .
我们报告了我们在玻璃体腔内使用贝伐单抗-bvzr（一种于 2019 年获得美国食品和药物管理局批准的贝伐单抗生物类似药，最近我们机构引入该药在儿童中进行标签外眼科使用）的初步经验。
这是一项机构审查委员会批准的单机构回顾性病例系列研究，纳入了 21 岁或以下接受至少一次玻璃体腔内生物类似贝伐单抗-bvzr 注射的儿科患者。
共纳入 9 例患者的 12 只眼，共进行了 13 次注射。注射的适应证包括早产儿视网膜病变（7/13）、脉络膜新生血管（3/13）、视网膜静脉阻塞（2/13）和 Coats 病（1/13）。在注射贝伐单抗-bvzr 后，所有患者均出现了阳性的临床反应。在中位随访 18 周时，未观察到注射后炎症、眼内压异常或眼内炎的发生。
在缺乏对照研究的情况下，本病例系列研究支持将玻璃体腔内使用贝伐单抗-bvzr 作为一种抗血管内皮生长因子治疗选择，包括在儿科人群和资源匮乏的环境中使用。
